Barclays’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Sell |
4,969
-55,093
| -92% | -$14.7M | ﹤0.01% | 2596 |
|
|
2025
Q4 | $14.8M | Sell |
60,062
-15,834
| -21% | -$3.33M | ﹤0.01% | 1422 |
|
|
2025
Q3 | $13.4M | Sell |
75,896
-16,975
| -18% | -$2.54M | ﹤0.01% | 1469 |
|
|
2025
Q2 | $12.8M | Buy |
92,871
+47,874
| +106% | +$7.03M | ﹤0.01% | 1399 |
|
|
2025
Q1 | $8.11M | Sell |
44,997
-7,432
| -14% | -$1.25M | ﹤0.01% | 1555 |
|
|
2024
Q4 | $8.21M | Sell |
52,429
-4,111
| -7% | -$729K | ﹤0.01% | 1723 |
|
|
2024
Q3 | $10.3M | Buy |
56,540
+37,452
| +196% | +$7.22M | ﹤0.01% | 1470 |
|
|
2024
Q2 | $3.51M | Sell |
19,088
-2,526
| -12% | -$424K | ﹤0.01% | 1753 |
|
|
2024
Q1 | $3.85M | Sell |
21,614
-42,565
| -66% | -$5.91M | ﹤0.01% | 2042 |
|
|
2023
Q4 | $7.96M | Buy |
64,179
+24,659
| +62% | +$2.73M | ﹤0.01% | 1705 |
|
|
2023
Q3 | $4.58M | Sell |
39,520
-7,107
| -15% | -$867K | ﹤0.01% | 1369 |
|
|
2023
Q2 | $5.47M | Buy |
46,627
+16,734
| +56% | +$1.71M | ﹤0.01% | 1298 |
|
|
2023
Q1 | $2.39M | Sell |
29,893
-6,455
| -18% | -$507K | ﹤0.01% | 2057 |
|
|
2022
Q4 | $2.88M | Buy |
36,348
+3,217
| +10% | +$239K | ﹤0.01% | 2002 |
|
|
2022
Q3 | $2.31M | Buy |
33,131
+31,925
| +2,647% | +$2.31M | ﹤0.01% | 1647 |
|
|
2022
Q2 | $79K | Sell |
1,206
-2,189
| -64% | -$136K | ﹤0.01% | 3864 |
|
|
2022
Q1 | $225K | Sell |
3,395
-22,466
| -87% | -$1.4M | ﹤0.01% | 3346 |
|
|
2021
Q4 | $1.81M | Buy |
25,861
+13,161
| +104% | +$766K | ﹤0.01% | 2451 |
|
|
2021
Q3 | $663K | Buy |
12,700
+9,334
| +277% | +$553K | ﹤0.01% | 3031 |
|
|
2021
Q2 | $228K | Sell |
3,366
-18,655
| -85% | -$1.3M | ﹤0.01% | 3487 |
|
|
2021
Q1 | $1.7M | Sell |
22,021
-2,914
| -12% | -$212K | ﹤0.01% | 2433 |
|
|
2020
Q4 | $1.5M | Sell |
24,935
-1,759
| -7% | -$87.8K | ﹤0.01% | 2470 |
|
|
2020
Q3 | $1.15M | Buy |
26,694
+19,890
| +292% | +$864K | ﹤0.01% | 2566 |
|
|
2020
Q2 | $282K | Sell |
6,804
-2,516
| -27% | -$121K | ﹤0.01% | 3806 |
|
|
2020
Q1 | $402K | Sell |
9,320
-1,487
| -14% | -$77.8K | ﹤0.01% | 3759 |
|
|
2019
Q4 | $598K | Buy |
10,807
+329
| +3% | +$16.1K | ﹤0.01% | 4136 |
|
|
2019
Q3 | $364K | Sell |
10,478
-460
| -4% | -$20.6K | ﹤0.01% | 4504 |
|
|
2019
Q2 | $440K | Sell |
10,938
-25,048
| -70% | -$819K | ﹤0.01% | 4433 |
|
|
2019
Q1 | $1.18M | Sell |
35,986
-1,403
| -4% | -$33.1K | ﹤0.01% | 3220 |
|
|
2018
Q4 | $777K | Buy |
+37,389
| New | +$783K | ﹤0.01% | 3379 |
|
Other funds holding KRYS
ACA
VPM
VCM
SCM
RG
Barclays's KRYS Position: Q1 2026 in Review
Barclays reduced its Krystal Biotech (KRYS) stake by 92% in Q1 2026, selling an estimated $14.7M and leaving 4,969 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2596.
Barclays first reported a position in KRYS in Q4 2018 and has held it in 30 quarters since. The position peaked at $14.8M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.
- Barclays held 4,969 shares of Krystal Biotech worth $1.28M as of Q1 2026.
- Barclays sold 55,093 Krystal Biotech shares in Q1 2026, an estimated $14.7M.
- Krystal Biotech made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2596 holding.
- Barclays first reported a position in Krystal Biotech in Q4 2018 and has held it in 30 quarters since.
- Barclays's Krystal Biotech position peaked at $14.8M in Q4 2025.
- 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.